ProfileGDS5678 / 1455921_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 43% 41% 41% 40% 40% 47% 45% 40% 40% 41% 41% 41% 41% 41% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0271843
GSM967853U87-EV human glioblastoma xenograft - Control 22.9526241
GSM967854U87-EV human glioblastoma xenograft - Control 32.9339141
GSM967855U87-EV human glioblastoma xenograft - Control 42.8758440
GSM967856U87-EV human glioblastoma xenograft - Control 52.8806840
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2056847
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1283245
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9156940
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8991940
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9272641
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9343641
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8992241
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9601241
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9345141